Diagnostic test: cardiac mri (gadolinium enhanced) (DrugBank: Gadolinium)
1 diseaseID | Disease name (Link within this page) | Number of trials |
---|---|---|
86 | Pulmonary arterial hypertension | 1 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT03344159 (ClinicalTrials.gov) | April 1, 2018 | 28/9/2017 | Spironolactone Therapy in Chronic Stable Right HF Trial | Spironolactone Therapy in Chronic Stable Right HF Trial | Chronic Right-Sided Heart Failure;Pulmonary Arterial Hypertension;Pulmonary Hypertension, Primary, 2;Pulmonary Hypertension, Primary, 3;Pulmonary Hypertension, Primary, 4;Cardiomyopathy Right Ventricular | Drug: Spironolactone;Drug: Placebo;Radiation: PET/CT Scan: Two PET scans using 1. C-11 HED and 2. N-13 Ammonia or rubidium-82;Diagnostic Test: Cardiac MRI (Gadolinium enhanced) | Ottawa Heart Institute Research Corporation | NULL | Suspended | 18 Years | N/A | All | 30 | Phase 4 | Canada |